Cobra works with QuiaPEG on PEGylation for extended half-life
Contract manufacturing organisation (CMO) Cobra Biologics is to produce biologics with an increased half-life using a PEGylation platform from biotech QuiaPEG.
Contract manufacturing organisation (CMO) Cobra Biologics is to produce biologics with an increased half-life using a PEGylation platform from biotech QuiaPEG.
Dispatches from DIA
As biopharma companies look to take advantage of a biosimilar market set to exceed $3.7bn by 2016, experts say the different regulations governing the follow-on biologics may be an issue as the markets become more developed.
Protein A will continue to be a major cost for mAb manufacturers despite efforts to develop alternatives say experts.
Alexion says it has provided NICE with the R&D and manufacturing information it asked for ahead of the second assessment of its £3,150-a-vial rare blood disorder drug Soliris next month.